UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

Journal of clinical oncology, 2017-05, Vol.35 (14), p.1542-1549

2017

Volltextzugriff (PDF)

KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Cancer treatment reviews, 2020-03, Vol.84, p.101974-101974, Article 101974

2020

Volltextzugriff (PDF)

Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer

Molecular cancer, 2021-06, Vol.20 (1), p.82-82, Article 82

2021

Volltextzugriff (PDF)

Gastrostomy tube dependence and patient‐reported quality of life outcomes based on type of treatment for human papillomavirus‐associated oropharyngeal cancer: Systematic review and meta‐analysis

Head & neck, 2021-11, Vol.43 (11), p.3681-3696

2021

Volltextzugriff (PDF)

Quality metrics for head and neck cancer treated with definitive radiotherapy and/or chemotherapy

Head & neck, 2021-06, Vol.43 (6), p.1788-1796

2021

Volltextzugriff (PDF)

Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck

The Laryngoscope, 2017-10, Vol.127 (10), p.2260-2264

2017

Volltextzugriff (PDF)

Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study

PloS one, 2015-11, Vol.10 (11), p.e0142225-e0142225

2015

Volltextzugriff (PDF)

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance

International journal of molecular sciences, 2019-12, Vol.21 (1), p.237

2019

Volltextzugriff (PDF)

African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer

Head & neck, 2022-10, Vol.44 (10), p.2069-2076

2022

Volltextzugriff (PDF)

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma

Oncotarget, 2017-05, Vol.8 (20), p.32918-32929

2017

Volltextzugriff (PDF)

Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes

Cancers, 2021-12, Vol.13 (24), p.6309

2021

Volltextzugriff (PDF)

Is this really just “fatigue”? A case series of immune‐related central adrenal insufficiency secondary to immune checkpoint inhibitors

Clinical case reports, 2018-07, Vol.6 (7), p.1278-1281

2018

Volltextzugriff (PDF)

The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer

Clinical lung cancer, 2022-01, Vol.23 (1), p.52-59

2022

Volltextzugriff (PDF)

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer

Lung cancer (Auckland), 2021-01, Vol.12, p.103-114

2021

Volltextzugriff (PDF)

Biomarkers predictive of response to pembrolizumab in head and neck cancer

Cancer medicine (Malden, MA), 2023-03, Vol.12 (6), p.6603-6614

2023

Volltextzugriff (PDF)

Anti‐PD‐1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report

Clinical case reports, 2021-12, Vol.9 (12), p.e05228-n/a

2021

Volltextzugriff (PDF)

Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation

Lung cancer (Auckland), 2018, Vol.9, p.85-90

2018

Volltextzugriff (PDF)

PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report

Journal for immunotherapy of cancer, 2016-11, Vol.4 (1), p.83, Article 83

2016

Volltextzugriff (PDF)

Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma—A single institution analysis of 54 patients

Clinical otolaryngology, 2019-07, Vol.44 (4), p.639-643

2019

Volltextzugriff (PDF)

Femoral metastasis in previously treated bladder cancer patient: A case report

Clinical case reports, 2022-09, Vol.10 (9), p.e6357-n/a

2022

Volltextzugriff (PDF)

NTRK3 mutation in secretory carcinoma of the parotid gland: A Case report

Clinical case reports, 2022-09, Vol.10 (9), p.e6243-n/a

2022

Volltextzugriff (PDF)

Immune checkpoint inhibitors: For how long do we need to release the brakes to achieve the optimum acceleration of immune-mediated anti-tumor response?

Oral oncology, 2020-02, Vol.101, p.104435, Article 104435

2020

Volltextzugriff (PDF)

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib

JTO clinical and research reports, 2021-02, Vol.2 (2), p.100125, Article 100125

2021

Volltextzugriff (PDF)

Associations between micro-geographic social vulnerability and disparities in cancer incidence

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18523-e18523

2023

Volltextzugriff (PDF)

674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A764-A764

2023

Volltextzugriff (PDF)

1 – 25 von 152

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(130)
Mit Volltextzugriff
(134)

Publikationsform

Sprache

Englisch
(152)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer

Gastrostomy tube dependence and patient‐reported quality of life outcomes based on type of treatment for human papillomavirus‐associated oropharyngeal cancer: Systematic review and meta‐analysis

Quality metrics for head and neck cancer treated with definitive radiotherapy and/or chemotherapy

Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck

Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance

African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma

Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes

Is this really just “fatigue”? A case series of immune‐related central adrenal insufficiency secondary to immune checkpoint inhibitors

The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer

Biomarkers predictive of response to pembrolizumab in head and neck cancer

Anti‐PD‐1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report

Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation

PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report

Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma—A single institution analysis of 54 patients

Femoral metastasis in previously treated bladder cancer patient: A case report

NTRK3 mutation in secretory carcinoma of the parotid gland: A Case report

Immune checkpoint inhibitors: For how long do we need to release the brakes to achieve the optimum acceleration of immune-mediated anti-tumor response?

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib

Associations between micro-geographic social vulnerability and disparities in cancer incidence

674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients

Suchergebnisse filtern